Intra-tumoral MTX110 for Glioblastoma

(MAGIC-G1 Trial)

Recruiting at 1 trial location

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Biodexa Pharmaceuticals

No Placebo Group

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests the safety of MTX110 in patients with recurrent glioblastoma. The drug is delivered directly to the tumor through a catheter to target it more effectively.

Research Team

Gary Shangold

Principal Investigator

Biodexa Pharmaceuticals

Eligibility Criteria

This trial is for patients with recurrent glioblastoma who are healthy enough for surgery and general anesthesia, have a life expectancy over 3 months, and haven't had certain recent treatments. Excluded are those with specific brain lesions, prior nitrosoureas treatment, inability to undergo MRI, or active treatment for another cancer.

Inclusion Criteria

You are expected to live for at least 3 more months.

My brain cancer has come back after treatment.

I am healthy enough to undergo surgery and anesthesia.

Exclusion Criteria

I haven't had chemotherapy or certain cancer drugs in the last 4 weeks.

I am scheduled for or currently receiving a second round of radiation for a returning tumor.

You are unable to have an MRI scan.

Treatment Details

Interventions

• MTX110 (Virus Therapy)

Trial Overview The study tests the safety of MTX110 when directly administered into the tumor site using a catheter system inserted surgically. The focus is on individuals whose glioblastoma has returned after previous treatments.

Participant Groups

Group I: Cohort B: MTX-110 with optional catheter repositioning Experimental Treatment 2 Interventions

Weekly dosing of MTX110 via CED until progression. At progression, optional catheter repositioning may occur, followed by continued weekly dosing of MTX110 until next progression/ unacceptable toxicity.

Group II: Cohort A: MTX-110 Experimental Treatment 2 Interventions

Weekly dosing of MTX110 via CED until progression/ unacceptable toxicity.

Who Is Running the Clinical Trial?

Biodexa Pharmaceuticals

Lead Sponsor

Trials

2

Recruited

30+

Midatech Ltd

Lead Sponsor

Trials

1

Recruited

4+